Ubrelvy (ubrogepant) is a medication used to treat migraine headaches in adults. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. Unlike older migraine treatments that constrict blood vessels, Ubrelvy works by blocking the activity of CGRP, a molecule involved in migraine pain [2].
How does Ubrelvy work for migraines?
Ubrelvy targets the CGRP pathway, which is believed to play a significant role in migraine development. By binding to the CGRP receptor, it prevents CGRP from exerting its effects, thereby reducing migraine pain and associated symptoms [2].
What is the difference between Ubrelvy and other migraine medications?
Ubrelvy is classified as an acute treatment for migraines, meaning it is taken when a migraine occurs to relieve symptoms [1]. This distinguishes it from preventive migraine medications, which are taken regularly to reduce the frequency and severity of migraines. Ubrelvy's mechanism of action, blocking CGRP, is also different from older acute treatments like triptans, which primarily work by constricting blood vessels [2].
When does Ubrelvy's patent expire?
Information regarding specific patent expiry dates for Ubrelvy is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patent information. Generally, patents protect a drug for a period, allowing for market exclusivity before generic versions can be developed [3].
What are the side effects of Ubrelvy?
Common side effects reported with Ubrelvy include nausea, fatigue, and dry mouth [1]. It is important for patients to discuss potential side effects with their healthcare provider.
Who makes Ubrelvy?
Ubrelvy is manufactured by AbbVie [4].
Can Ubrelvy be used for migraine prevention?
Ubrelvy is indicated for the acute treatment of migraine and is not approved for migraine prevention [1].
Sources:
1. https://www.ubrelvy.com/
2. https://www.drugpatentwatch.com/drug/ubrogepant
3. https://www.drugpatentwatch.com/
4. https://www.abbvie.com/